X
[{"orgOrder":0,"company":"Altos Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea\u00ae Biosimilar in Neovascular Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Altos Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altos Biologics Files for Approval of Aflibercept Biosimilar","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Altos Biologics
Filters
Companies By Therapeutic Area
Details:
ALT-L9 (aflibercept), biosimilar of Eylea, is a recombinant fusion protein which inhibits VEGF A. It is being evaluated in phase 3 clinical studies for the treatment of Neovascular (Wet) AMD.
Lead Product(s):
Aflibercept
Therapeutic Area: Ophthalmology
Product Name: ALT-L9
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 01, 2024
Details:
ALT-L9 (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s):
Aflibercept
Therapeutic Area: Ophthalmology
Product Name: ALT-L9
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 22, 2023